2. Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2016 Jul 14;37(27):2129-2200. doi: 10.1093/eurheartj/ ehw128.

3. Mosterd A., Hoes A.W. Clinical epidemiology of heart failure. Heart. 2007 Sep;93(9):1137-46. doi: 10.1136/ hrt.2003.025270.

4. Redfield M.M., Jacobsen S.J., Burnett C.Jr et al. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. JAMA. 2003 Jan 8;289(2):194-202. doi: 10.1001/jama.289.2.194.

5. Bleumink G.S., Knetsch A.M., Sturkenboom M.C. et al. Quantifying the heart failure epidemic: prevalence, incidence rate, lifetime risk and prognosis of heart failure The Rotterdam Study. Eur Heart J. 2004 Sep;25(18):1614-9. doi: 10.1016/j.ehj.2004.06.038.

6. Ceia F., Fonseca C., Mota T. et al. Prevalence of chronic heart failure in Southwestern Europe: the EPICA study. Eur J Heart Fail. 2002 Aug;4(4):531-9. doi: 10.1016/s1388-9842(02)00034-x..

7. Фомин И.В., Беленков Ю.Н., Мареев В.Ю. и др. Распространенность хронической сердечной недо- статочности в Европейской части Российской Федерации – данные ЭПОХА–ХСН. Журнал Сердечная недостаточность. 2006;7(3):112–5.

8. Артемьева Е.Г., Маленкова В.Ю., Фролова Е.В. Распространенность артериальной гипертензии при хронической сердечной недостаточности в Чувашской Республике. Медицинский альманах. 2011;(16):51–4.

9. Сергеева Е.М., Малишевский М.В., Васина А.А. и др. Лечение хронической сердечной недостаточ- ности в первичном звене муниципального здравоохранения в г. Тюмени. Медицинская наука и обра- зование Урала. 2015;16(4):32–4.

10. Шакирова Р.М., Галявич А.С., Камалов Г. М. Распространенность сердечно-сосудистых заболеваний и сахарного диабета в республике Татарстан и их взаимосвязь с симптомами хронической сердечной недостаточности. Журнал Сердечная недостаточность. 2005;6(2):72–3.

11. Смирнова Е.А. Изучение распространенности и этиологии хронической сердечной недостаточности в Рязанской области. Российский кардиологический журнал. 2010;(2):78–83. https://doi.org/10.15829/1560-4071-2010-2-78-83.

12. Бабанская Е.Б., Меньшикова Л.В., Дац Л.С. Эпидемиология хронической сердечной недостаточности в городе Иркутске. Бюллетень ВСНЦ СО РАМН. 2012;(5–1):25–8.

13. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;(8):7–13. doi:10.15829/1560-4071- 2016-8-7-13

14. Maggioni A.P., Dahlstrom U., Filippatos G. et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013 Jul;15(7):808-17. doi: 10.1093/eurjhf/hft050.

15. Gerber Y., Weston S.A., Redfield M.M. et al. A contemporary appraisal of the heart failure epidemic in Olmsted County, Minnesota, 2000 to 2010. JAMA Intern Med. 2015 Jun;175(6):996-1004. doi: 10.1001/ jamainternmed.2015.0924

16. GOLD-2017 Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017; http://goldcopd.org.

17. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2019; https://goldcopd.org/wp-content/uploads/2018/11/GOLD-2019- v1.7-FINAL-14Nov2018-WMS.pdf Accessed January 24, 2019.

18. Cosentino E.R., Degli Esposti D., Miceli R. et al. Coexisting Heart Failure and Chronic Obstructive Pulmonary Disease: Report of Two Cases Treated with Indacaterol/Glycopyrronium. Respiration. 2018;95 Suppl 1:3-5. doi: 10.1159/000487169.

19. Wheaton A.G., Cunningham T.J., Ford E.S. et al. Employment and activity limitations among adults with chronic obstructive pulmonary disease--United States, 2013. MMWR Morb Mortal Wkly Rep. 2015 Mar 27;64(11):289-95. PMID: 25811677.

20. Айсанов З.Р., Авдеев С.Н., Архипов В.В. и др. Национальные клинические рекомендации по диа- гностике и лечению хронической обструктивной болезни легких: алгоритм принятия клинических решений. Пульмонология. 2017;27(1):13-20. https://doi.org/10.18093/0869-0189-2017-27-1-13-20.

21. Lozano R., Naghavi M., Foreman K. et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2095-128. doi: 10.1016/S0140-6736(12)61728-0.

22. Anthonisen N.R., Connett J.E., Enright P.L., Manfreda J. Lung Health Study Research Group. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9. doi: 10.1164/rccm.2110093.

23. Mannino D.M., Thorn D., Swensen A. et al. Prevalence and outcomes of diabetes, hypertension, andcardiovascular disease in chronic obstructive pulmonary disease. Eur Respir J. 2008 Oct;32(4):962-9. doi: 10.1183/09031936.00012408.

24. Finkelstein J., Cha E., Scharf S.M. Chronic obstructive pulmonary disease as an independent risk factor for cardiovascular morbidity. Int J Chron Obstruct Pulmon Dis. 2009;4:337-49. PMID: 19802349.

25. Lahousse L., Niemeijer M.N., van den Berg M.E. et al. Chronic obstructive pulmonary disease and sudden cardiac death: the Rotterdam study. Eur Heart J. 2015 Jul 14;36(27):1754-61. doi: 10.1093/eurheartj/ ehv121.

26. Valk M.J., Broekhuizen B.D., Mosterd A. et al. COPD in patients with stable heart failure in the primary care setting. Int J Chron Obstruct Pulmon Dis. 2015 Jun 26;10:1219-24. doi: 10.2147/COPD.S77085.

27. Pellicori P., Salekin D., Pan D. et al. This patient is not breathing properly: is this COPD, heart failure, or neither? Expert Rev Cardiovasc Ther. 2017 May;15(5):389-396. doi: 10.1080/14779072.2017.1317592.

28. Cleland J.G., Pellicori P. Defining diastolic heart failure and identifying effective therapies. JAMA. 2013 Feb 27;309(8):825-6. doi: 10.1001/jama.2013.1569.

29. Rodríguez L.A., Wallander M.A., Martín-Merino E. et al. Heart failure, myocardial infarction, lung cancer and death in COPD patients: a UK primary care study. Respir Med. 2010 Nov;104(11):1691-9. doi: 10.1016/j.rmed.2010.04.018.

30. Обрезан А.Г., Куколь Л.В., Эрднеев Б.А. Хроническая обструктивная болезнь легких и коморбидные кардиоваскулярные заболевания у лиц пожилого и старческого возраста: проблемы диагностики лечения (обзор литературы). Вестник СПбГУ. 2010;11(2):51-66.

31. Ather S., Chan W., Bozkurt B. et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol. 2012 Mar 13;59(11):998-1005. doi: 10.1016/j.jacc.2011.11.040.

32. Tannus-Silva D.G., Rabahi M.F. State of the Art Review of the Right Ventricle in COPD Patients: It is Time to Look Closer. Lung. 2017 Feb;195(1):9-17. doi: 10.1007/s00408-016-9961-5.]

33. Kaszuba E., Odeberg H., Råstam L. et al. Heart failure and levels of other comorbidities in patients with chronic obstructive pulmonary disease in a Swedish population: a register-based study. BMC Res Notes. 2016 Apr 12;9:215. doi: 10.1186/s13104-016-2008-4.

34. Cazzola M., Calzetta L., Bettoncelli G. et al. Cardiovascular disease in asthma and COPD: a population- based retrospective cross-sectional study. Respir Med. 2012 Feb;106(2):249-56. doi: 10.1016/j. rmed.2011.07.021,

35. Rutten F.H., Cramer M.J., Lammers J.W. et al. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006 Nov;8(7):706-11. doi: 10.1016/j.ejheart.2006.01.010.

36. Curkendall S.M., DeLuise C., Jones J.K. et al. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann Epidemiol. 2006Jan;16(1):63-70. doi: 10.1016/j.annepidem.2005.04.008.

37. Jensen H.H., Godtfredsen N.S., Lange P. et al. Potential misclassification of causes of death from COPD. Eur Respir J. 2006 Oct;28(4):781-5. doi: 10.1183/09031936.06.00152205.

38. Müllerova H., Agusti A., Erqou S. et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013 Oct;144(4):1163-1178. doi: 10.1378/chest.12-2847.

39. Sin D.D., Man S.F. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation. 2003 Mar 25;107(11):1514-9. doi: 10.1161/01.cir.0000056767.69054.b3

40. Anthonisen N.R., Connett J.E., Enright P.L. et al. Hospitalizations and mortality in the Lung Health Study. Am J Respir Crit Care Med. 2002 Aug 1;166(3):333-9. doi: 10.1164/rccm.2110093.

41. Zvezdin B., Milutinov S., Kojicic M. et al. A postmortem analysis of major causes of early death in patients hospitalized with COPD exacerbation. Chest. 2009 Aug;136(2):376-380. doi: 10.1378/chest.08-2918.

42. Testa G., Cacciatore F., Bianco A. et al. Chronic obstructive pulmonary disease and long-term mortality in elderly subjects with chronic heart failure. Aging Clin Exp Res. 2017 Dec;29(6):1157-1164. doi: 10.1007/ s40520-016-0720-5.

43. Griffo R., Spanevello A., Temporelli P.L. et al. Frequent coexistence of chronic heart failure and chronic obstructive pulmonary disease in respiratory and cardiac outpatients: Evidence from SUSPIRIUM, a multicentre Italian survey. Eur J Prev Cardiol. 2017 Apr;24(6):567-576. doi: 10.1177/2047487316687425.

44. Iorio A., Senni M., Barbati G. et al. Prevalence and prognostic impact of non-cardiac co-morbidities in heart failure outpatients with preserved and reduced ejection fraction: a community-based study. Eur J Heart Fail. 2018 Sep;20(9):1257-1266. doi: 10.1002/ejhf.1202.

45. Cook S., Togni M., Schaub M.C. et al. High heart rate: a cardiovascular risk factor? Eur Heart J. 2006 Oct;27(20):2387-93. doi: 10.1093/eurheartj/ehl259 .

46. MacNee W. Pathophysiology of cor pulmonale in chronic obstructive pulmonary disease. Part One. Am J Respir Crit Care Med. 1994 Sep;150(3):833-52. doi:10.1164/ajrccm.150.3.8087359

47. WHO (1963) Chronic cor pulmonale, report of an expert committee. Circulation 27:594–615. doi:10.1161/01. CIR.27.4.594

48. Hilde J.M., Skjørten I., Grøtta O.J. et al. Right ventricular dysfunction and remodeling in chronic obstructive pulmonary disease without pulmonary hypertension. J Am Coll Cardiol. 2013 Sep 17;62(12):1103-1111. doi: 10.1016/j.jacc.2013.04.091.

49. Rubin L.J. Cor pulmonale revisited. J Am Coll Cardiol. 2013 Sep 17;62(12):1112-1113. doi: 10.1016/j. jacc.2013.06.034.

50. Kent B.D., Mitchell P.D., McNicholas W.T. Hypoxemia in patients with COPD: cause, effects, and diseaseprogression. Int J Chron Obstruct Pulmon Dis. 2011;6:199-208. doi: 10.2147/COPD.S10611.

51. Joppa P., Petrasova D., Stancak B. et al. Systemic inflammation in patients with COPD and pulmonary hypertension. Chest. 2006 Aug;130(2):326-33. doi: 10.1378/chest.130.2.326.

52. Nakamura A., Kasamatsu N., Hashizume I. et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary vascular resistance in patients with chronic emphysema. Respiration. 2000;67(5):502-6. doi: 10.1159/000067463.

53. Guder G., Rutten F.H. Comorbidity of heart failure and chronic obstructive pulmonary disease: more than coincidence. Curr Heart Fail Rep. 2014 Sep;11(3):337-46. doi: 10.1007/s11897-014-0212-x.

54. Klinger J.R., Hill N.S. Right ventricular dysfunction in chronic obstructive pulmonary disease. Evaluation and management. Chest. 1991 Mar;99(3):715-23. doi: 10.1378/chest.99.3.715.

55. Burghuber O., Bergmann H., Silberbauer K. et al. Right ventricular performance in chronic air flow obstruction. Respiration. 1984;45(2):124-30. PMID: 6729257.

56. Morrison D.A., Adcock K., Collins C.M. et al. Right ventricular dysfunction and the exercise limitation of chronic obstructive pulmonary disease. J Am Coll Cardiol. 1987 Jun;9(6):1219-29. doi: 10.1016/s0735- 1097(87)80459-x

57. Matsuoka S., Washko G.R., Yamashiro T. et al. Pulmonary hypertension and computed tomography measurement of small pulmonary vessels in severe emphysema. Am J Respir Crit Care Med. 2010 Feb 1;181(3):218-25. doi: 10.1164/rccm.200908-1189OC.

58. Kolb T.M., Hassoun P.M. Right ventricular dysfunction in chronic lung disease. Cardiol Clin. 2012 May;30(2):243-56. doi: 10.1016/j.ccl.2012.03.005.

59. Das M., Tapadar S.R., Mahapatra A.B. et al. Assessment of RV Function in Patients of (COPD). J Clin Diagn Res. 2014 Mar;8(3):11-3. doi: 10.7860/JCDR/2014/6440.4090.

60. Vonk-Noordegraaf A., Marcus J.T., Holverda S. et al. Early changes of cardiac structure and function in COPD patients with mild hypoxemia. Chest. 2005 Jun;127(6):1898-903. doi: 10.1378/chest.127.6.1898.

61. Himelman R.B., Struve S.N., Brown J.K. et al. Improved recognition of cor pulmonale in patients with severe chronic obstructive pulmonary disease. Am J Med. 1988 May;84(5):891-8. doi: 10.1016/0002- 9343(88)90068-x.

62. Matthay R.A., Berger H.J. Cardiovascular performance in chronic obstructive pulmonary diseases. Med Clin North Am. 1981 May;65(3):489-524. doi: 10.1016/s0025-7125(16)31511-5.

63. Fenster B.E., Holm K.E., Weinberger H.D. et al. Right ventricular diastolic function and exercise capacity in COPD. Respir Med. 2015 Oct;109(10):1287-92. doi: 10.1016/j.rmed.2015.09.003.

64. Kang H., Bae B.S., Kim J.H. et al. The relationship between chronic atrial fibrillation and reduced pulmonary function in cases of preserved left ventricular systolic function. Korean Circ J. 2009Sep;39(9):372-7. doi: 10.4070/kcj.2009.39.9.372.

65. Haissaguerre M., Jais P., Shah D.C. et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66. doi: 10.1056/ NEJM199809033391003.

66. Melnichenko O.V., Nekrasov A.A., Kuznetsov A.N. Factors associated with the development of atrial fibrillation in chronic obstructive pulmonary disease. IJBM 2011;1(2):71-73.] 10 Ли.=

67. Funk G.С., Lang I., Schenk P. et al. Left ventricular diastolic dysfunction in patients with COPD in the presence and absence of elevated pulmonary arterial pressure. Chest. 2008 Jun;133(6):1354-1359. doi: 10.1378/chest.07-2685.

68. Huang Y.S., Feng Y.C., Zhang J. et al. Impact of chronic obstructive pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients. Clin Interv Aging. 2014 Dec 19;10:81-7. doi: 10.2147/ CIA.S71878.

69. Caram L.M., Ferrari R., Naves C.R. et al. Association between left ventricular diastolic dysfunction and severity of chronic obstructive pulmonary disease. Clinics (Sao Paulo). 2013 Jun;68(6):772-6. doi: 10.6061/clinics/2013(06)08.

70. Watz H., Waschki B., Meyer T. et al. Decreasing cardiac chamber sizes and associated heart dysfunction in COPD: role of hyperinflation. Chest. 2010 Jul;138(1):32-8. doi: 10.1378/chest.09-2810.

71. Sabit R., Bolton C.E., Fraser A.G. et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010 Aug;104(8):1171-8. doi: 10.1016/j.rmed.2010.01.020.

72. Barr R.G., Bluemke D.A., Ahmed F.S. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010 Jan 21;362(3):217-27. doi: 10.1056/NEJMoa0808836.

73. Smith B.M., Prince M.R., Hoffman E.A. et al. Impaired left ventricular filling in COPD and emphysema: is it the heart or the lungs? The Multi-Ethnic Study of Atherosclerosis COPD Study. Chest. 2013 Oct;144(4):1143-1151. doi: 10.1378/chest.13-0183.

74. Smith B.M., Kawut S.M., Bluemke D.A. et al. Pulmonary hyperinflation and left ventricular mass: the Multi-Ethnic Study of Atherosclerosis COPD Study. Circulation. 2013 Apr 9;127(14):1503-11, 1511e1-6. doi: 10.1161/CIRCULATIONAHA.113.001653.].

75. MacNee W. Accelerated lung aging: a novel pathogenic mechanism of chronic obstructive pulmonary disease (COPD). Biochem Soc Trans. 2009 Aug;37(Pt 4):819-23. doi: 10.1042/BST0370819. .

76. Portillo K., Abad-Capa J., Ruiz-Manzano J. Chronic obstructive pulmonary disease and left ventricle. Arch Bronconeumol. 2015 May;51(5):227-34. doi: 10.1016/j.arbres.2014.03.012.

77. Barr R.G., Bluemke D.A., Ahmed F.S. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010 Jan 21;362(3):217-27. doi: 10.1056/NEJMoa0808836.

78. Jankowich M.D., Rounds S.I.S. Combined pulmonary fibrosis and emphysema syndrome: a review. Chest.2012 Jan;141(1):222-231. doi: 10.1378/chest.11-1062.

79. Peinado V.I., Barbera J.A., Ramirez J. et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J Physiol. 1998 Jun;274(6):L908-13. doi: 10.1152/ajplung.1998.274.6.L908.

80. Maclay J.D., McAllister D.A., Johnston S. et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax. 2011 Sep;66(9):769-74. doi: 10.1136/thx.2010.157529.

81. Mills N.L., Miller J.J., Anand A. et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk. Thorax. 2008 Apr;63(4):306-11. doi: 10.1136/thx.2007.083493.

82. Andreas S., Anker S.D., Scanlon P.D. et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005 Nov;128(5):3618-24. doi: 10.1378/chest.128.5.3618.

83. Churg A., Zhou S., Wright J.L. Series «matrix metalloproteinases in lung health and disease»: Matrix metalloproteinases in COPD. Eur Respir J. 2012 Jan;39(1):197-209. doi: 10.1183/09031936.00121611.

84. Savale L., Chaouat A., Bastuji-Garin S. et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009 Apr 1;179(7):566-71. doi: 10.1164/rccm.200809-1398OC.

85. Barnes P.J., Celli B.R. Systemic manifestations and comorbidities of COPD. Eur Respir J. 2009 May;33(5):1165-85. doi: 10.1183/09031936.00128008.

86. Bhattacharyya P., Acharjee D., Ray S.N. et al. Left ventricular diastolic dysfunction in COPD may manifest myocardial ischemia. COPD. 2012 Jun;9(3):305-9. doi: 10.3109/15412555.2012.661805.

87. Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013 Mar;143(3):798-807. doi: 10.1378/chest.12-0938.

88. Larsen K.O., Sjaastad I., Svindland A. et al. Alveolar hypoxia induces left ventricular diastolic dysfunction and reduces phosphorylation of phospholamban in mice. Am J Physiol Heart Circ Physiol. 2006 Aug;291(2):H507-16. doi: 10.1152/ajpheart.00862.2005

89. Thomson A.J., Drummond G., Waring W.S. et al. Effects of shortterm isocapnic hyperoxia and hypoxia on cardiovascular function. J Appl Physiol.2006;101:809–16. doi:10.1152/japplphysiol.01185.2005

90. Lattimore J.D., Wilcox I., Nakhla S. et al. Repetitive hypoxia increases lipid loading in human macrophages-a potentially atherogenic effect. Atherosclerosis. 2005 Apr;179(2):255-9. doi: 10.1016/j. atherosclerosis.2004.11.010.

91. Heindl S., Lehnert M., Criée C.P. et al. Marked sympathetic activation in patients with chronic respiratory failure. Am J Respir Crit Care Med. 2001 Aug 15;164(4):597-601. doi: 10.1164/ajrccm.164.4.2007085

92. Echave J.M., Martin-Escudero J.C., Anton E. et al. Comorbidity in COPD in Spain. Am J Respir Crit CareMed. 2009;179: А1462.

93. McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC guidelines for the diagnosis and treatment of acuteand chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2012 Aug;14(8):803-69. doi: 10.1093/eurjhf/hfs105.

94. Andreas S., Anker S.D., Scanlon P.D. et al. Neurohumoral activation as a link to systemic manifestations of chronic lung disease. Chest. 2005 Nov;128(5):3618-24. doi: 10.1378/chest.128.5.3618.

95. Forth R., Montgomery H. ACE in COPD: a therapeutic target? Thorax. 2003 Jul;58(7):556-8. doi: 10.1136/ thorax.58.7.556

96. Mancini G.B., Khalil N. Angiotensin II type 1 receptor blocker inhibits pulmonary injury. Clin Invest Med. 2005 Jun;28(3):118-26. PMID: 16021985

97. Aronow W.S. Treatment of heart failure in older persons. Dilemmas with coexisting conditions: diabetes mellitus, chronic obstructive pulmonary disease, and arthritis. Congest Heart Fail. 2003 May- Jun;9(3):142-7. PMID: 12826772. 71= Guazzi M. Alveolar-capillary membrane dysfunction in heart failure: evidence of a pathophysiologic role. Chest. 2003 Sep;124(3):1090-102. doi: 10.1378/chest.124.3.1090.

98. Sakamaki F., Satoh T., Nagaya N. et al. Abnormality of left ventricular sympathetic nervous function assessed by (123)I-metaiodobenzylguanidine imaging in patients with COPD. Chest. 1999 Dec;116(6):1575- 81. doi: 10.1378/chest.116.6.1575

99. Jackson G., Gibbs C.R., Davies M.K. et al. ABC of heart failure. Pathophysiology. BMJ. 2000 Jan 15;320(7228):167-70. doi: 10.1136/bmj.320.7228.167

100. Mann D.L., Bristow M.R. Mechanisms and models in heart failure: the biomechanical model and beyond.Circulation. 2005 May 31;111(21):2837-49. doi: 10.1161/CIRCULATIONAHA.104.500546.

101. Gosker H.R., Lencer N.H., Franssen F.M. et al. Striking similarities in systemic factors contributing to decreased exercise capacity in patients with severe chronic heart failure or COPD. Chest. 2003 May;123(5):1416-24. doi: 10.1378/chest.123.5.1416.

102. Schols A.M. Nutritional and metabolic modulation in chronic obstructive pulmonary disease management.Eur Respir J Suppl. 2003 Nov;46:81s-86s. PMID: 14621110.

103. Jörgensen K., Houltz E., Westfelt U. et al. Effects of lung volume reduction surgery on left ventricular diastolic filling and dimensions in patients with severe emphysema. Chest. 2003 Nov;124(5):1863-70. doi: 10.1378/chest.124.5.1863.

104. Jörgensen K., Müller M.F., Nel J., Upton R.N. et al. Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest. 2007 Apr;131(4):1050-7. doi: 10.1378/chest.06-2245.

105. Ли В.В., Тимофеева Н.Ю., Задионченко В.С. и др. Современные аспекты ремоделирования сердца у больных хронической обструктивной болезнью легких. Рациональная фармакотерапия в кардиологии 2018;14(3):379-386. doi: 10.20996/1819-6446-2018-14-3-379-386.

106. Кароли Н.А., Ребров А.П. Коморбидность у больных хронической обструктивной болезнью легких: место кардиоваскулярной патологии. Рациональная фармакотерапия в кардиологии. 2009;5(4):9-16. 107.Kubota Y., Asai K., Murai K. et al. COPD advances in left ventricular diastolic dysfunction. Int J ChronObstruct Pulmon Dis. 2016 Mar 29;11:649-55. doi: 10.2147/COPD.S101082.

108. Alter P., van de Sand K., Nell C. et al. Airflow limitation in COPD is associated with increased left ventricular wall stress in coincident heart failure. Respir Med. 2015 Sep;109(9):1131-7. doi: 10.1016/j. rmed.2015.07.012.

109. Boussuges A., Pinet C., Molenat F. et al. Left atrial and ventricular filling in chronic obstructive pulmonary disease. An echocardiographic and Doppler study. Am J Respir Crit Care Med. 2000 Aug;162(2 Pt 1):670-5. doi: 10.1164/ajrccm.162.2.9908056.

110. Jörgensen K., Müller M.F., Nel J., Upton R.N. et al. Reduced intrathoracic blood volume and left and right ventricular dimensions in patients with severe emphysema: an MRI study. Chest. 2007 Apr;131(4):1050-7. doi: 10.1378/chest.06-2245.

111. O’Donnell D.E. Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease. Proc Am Thorac Soc. 2006 Apr;3(2):180-4. DOI: 10.1513/pats.200508-093DO.

112. Vassaux C., Torre-Bouscoulet L., Zeineldine S. et al. Effects of hyperinflation on the oxygen pulse as a marker of cardiac performance in COPD. Eur Respir J. 2008 Nov;32(5):1275-82. doi: 10.1183/09031936.00151707.

113. Tzani P., Aiello M., Elia D. et al. Dynamic hyperinflation is associated with a poor cardiovascular response to exercise in COPD patients. Respir Res. 2011 Nov 10;12:150. doi: 10.1186/1465-9921-12-150.

114. Lammi M.R., Ciccolella D., Marchetti N. et al. Increased oxygen pulse after lung volume reduction surgery is associated with reduced dynamic hyperinflation. Eur Respir J. 2012 Oct;40(4):837-43. doi: 10.1183/09031936.00169311.

115. Barr R.G., Bluemke D.A., Ahmed F.S. et al. Percent emphysema, airflow obstruction, and impaired left ventricular filling. N Engl J Med. 2010 Jan 21;362(3):217-27. doi: 10.1056/NEJMoa0808836.

116. Caram L.M., Ferrari R., Naves C.R. et al. Association between left ventricular diastolic dysfunction and severity of chronic obstructive pulmonary disease. Clinics (Sao Paulo). 2013 Jun;68(6):772-6. doi: 10.6061/clinics/2013(06)08.

117. Abeer M. Rawy, Diaa Fathalla. Left ventricular diastolic dysfunction in patients with chronic obstructive pulmonary disease (COPD), prevalence and association with disease severity: Using tissue Doppler study. Egypt. J. Chest Dis. Tuberc. 2015;64:785–92. https://doi.org/10.1016/j.ejcdt.2015.06.010.

118. Горелик И.Л., Калманова Е.Н., Айсанов З.Р. и др. Диагностика ранних признаков ремоделированиясердца у пациентов с ХОБЛ. Практическая медицина. 2011;3(51): 72-77.

119. Pela G., Li Calzi M., Pinelli S. et al. Left ventricular structure and remodeling in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016 May 13;11:1015-22. doi: 10.2147/COPD.S102831.

120. Huang Y.S., Feng Y.C., Zhang J. et al. Impact of chronic obstructive pulmonary diseases on left ventricular diastolic function in hospitalized elderly patients. Clin Interv Aging. 2014 Dec 19;10:81-7. doi: 10.2147/ CIA.S71878.

121. Marcun R., Stankovic I., Vidakovic R. et al. Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Intern Emerg Med. 2016 Jun;11(4):519-27. doi: 10.1007/s11739-015-1319-0

122. Rutten F.H., Moons K.G., Cramer M.J. et al. Recognising heart failure in elderly patients with stable chronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005 Dec 10;331(7529):1379. doi: 10.1136/bmj.38664.661181.55.

123. Некрасов А.А., Кузнецов А.Н., Мельниченко О.В. и др. Ремоделирование сердца у больных хрониче- ской обструктивной болезнью легких. Медицинский альманах. 2011;3(16):112-115.

124. McAllister D.A., Maclay J.D., Mills N.L. et al. Arterial stiffness is independently associated with emphysema severity in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2007 Dec 15;176(12):1208-14. doi: 10.1164/rccm.200707-1080OC.

125. Sabit R., Bolton C.E., Fraser A.G. et al. Sub-clinical left and right ventricular dysfunction in patients with COPD. Respir Med. 2010 Aug;104(8):1171-8. doi: 10.1016/j.rmed.2010.01.020.

126. Assayag P., Benamer H., Aubry P. et al. Alteration of the alveolar-capillary membrane diffusing capacity in chronic left heart disease. Am J Cardiol. 1998 Aug 15;82(4):459-64. doi: 10.1016/s0002- 9149(98)00360-9.

127. West J.B., Mathieu-Costello O. Stress failure of pulmonary capillaries: role in lung and heart disease.Lancet. 1992 Sep 26;340(8822):762-7. doi: 10.1016/0140-6736(92)92301-u.

128. Guglin M., Khan H. Pulmonary hypertension in heart failure. J Card Fail. 2010 Jun;16(6):461-74. doi: 10.1016/j.cardfail.2010.01.003.

129. Guder G., Rutten F.H., Brenner S. et al. The impact of heart failure on the classification of COPD severity.J Card Fail. 2012 Aug;18(8):637-44. doi: 10.1016/j.cardfail.2012.05.008

130. Faggiano P. Abnormalities of pulmonary function in congestive heart failure. Int J Cardiol. 1994 Mar 15;44(1):1-8. doi: 10.1016/0167-5273(94)90060-4.

131. Dimopoulou I., Daganou M., Tsintzas O.K. et al. Effects of severity of long-standing congestive heart failure on pulmonary function. Respir Med. 1998 Dec;92(12):1321-5. PMID: 10197224.

132. Puri S., Dutka D.P., Baker B.L. et al. Acute saline infusion reduces alveolar-capillary membrane conductance and increases airflow obstruction in patients with left ventricular dysfunction. Circulation.1999 Mar 9;99(9):1190-6. doi: 10.1161/01.cir.99.9.1190.

133. Light R.W., George R.B. Serial pulmonary function in patients with acute heart failure. Arch Intern Med.1983 Mar;143(3):429-33. PMID: 6830378.

134. Petermann W., Barth J., Entzian P. Heart failure and airway obstruction. Int J Cardiol. 1987 Nov;17(2):207- 9. doi: 10.1016/0167-5273(87)90132-x.

135. Kee K., Naughton M.T. Heart failure and the lung. Circ J. 2010 Nov;74(12):2507-16. doi: 10.1253/circj. cj-10-0869.

136. Brenner S., Güder G., Berliner D. et al. Airway obstruction in systolic heart failure--COPD or congestion?Int J Cardiol. 2013 Oct 3;168(3):1910-6. doi: 10.1016/j.ijcard.2012.12.083.

137. Macchia A., Rodriguez Moncalvo J.J., Kleinert M. et al. Unrecognised ventricular dysfunction in COPD. Eur Respir J. 2012 Jan;39(1):51-8. doi: 10.1183/09031936.00044411.

138. McCullough P.A., Hollander J.E., Nowak R.M. et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003 Mar;10(3):198-204. PMID: 12615582.

139. Rutten F.H., Cramer M.J., Grobbee D.E. et al. Unrecognized heart failure in elderly patients with stable chronic obstructive pulmonary disease. Eur Heart J. 2005 Sep;26(18):1887-94. doi: 10.1093/eurheartj/ ehi291.

140. Chhabra S.K., Gupta M. Coexistent chronic obstructive pulmonary disease-heart failure: mechanisms, diagnostic and therapeutic dilemmas. Indian J Chest Dis Allied Sci. 2010 Oct-Dec;52(4):225-38.

141. Smith M.C., Wrobel J.P. et al. Epidemiology and clinical impact of major comorbidities in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2014 Aug 27;9:871-88. doi: 10.2147/COPD.S49621.

142. Mascarenhas J., Azevedo A., Bettencourt P. Coexisting chronic obstructive pulmonary disease and heart failure: implications for treatment, course and mortality. Curr Opin Pulm Med. 2010 Mar;16(2):106-11. doi: 10.1097/MCP.0b013e328335dc90.

143. Hawkins N.M., Petrie M.C., Jhund P.S. et al. Heart failure and chronic obstructive pulmonary disease: diagnostic pitfalls and epidemiology. Eur J Heart Fail. 2009 Feb;11(2):130-9. doi: 10.1093/eurjhf/hfn013. 144.Milne E.N., Bass H. Roentgenologic and functional analysis of combined chronic obstructive pulmonary disease and congestive cardiac failure. Invest Radiol. 1969 May-Jun;4(3):129-47. doi: 10.1097/00004424-196905000-00001.

145. Hublitz U.F., Shapiro J.H. Atypical pulmonary patterns of congestive failure in chronic lung disease. The influence of pre-existing disease on the appearance and distribution of pulmonary edema. Radiology. 1969 Nov;93(5):995-1006. doi: 10.1148/93.5.995.

146. Gehlbach B.K., Geppert E. The pulmonary manifestations of left heart failure. Chest. 2004 Feb;125(2):669- 82. doi: 10.1378/chest.125.2.669.

147. Milne E.N. Correlation of physiologic findings with chest roentgenology. Radiol Clin North Am. 1973 Apr;11(1):17-47. PMID: 4570722.

148. Roberts E., Ludman A.J., Dworzynski K. et al. The diagnostic accuracy of the natriuretic peptides in heart failure: systematic review and diagnostic meta-analysis in the acute care setting. BMJ. 2015 Mar 4;350:h910. doi: 10.1136/bmj.h910.

149. Maisel A., Mueller C., Adams K. Jr et al. State of the art: using natriuretic peptide levels in clinical practice. Eur J Heart Fail. 2008 Sep;10(9):824-39. doi: 10.1016/j.ejheart.2008.07.014.

150. Madamanchi C., Alhosaini H., Sumida A. et al. Obesity and natriuretic peptides, BNP and NT-proBNP: mechanisms and diagnostic implications for heart failure. Int J Cardiol. 2014 Oct 20;176(3):611-7. doi: 10.1016/j.ijcard.2014.08.007.

151. Jaiswal A., Chichra A., Nguyen V.Q. et al. Challenges in the Management of Patients with Chronic Obstructive Pulmonary Disease and Heart Failure With Reduced Ejection Fraction. Curr Heart Fail Rep. 2016 Feb;13(1):30-6. doi: 10.1007/s11897-016-0278-8.

152. Le Jemtel T.H., Padeletti M., Jelic S. Diagnostic and therapeutic challenges in patients with coexistent chronic obstructive pulmonary disease and chronic heart failure. J Am Coll Cardiol. 2007 Jan 16;49(2):171-80. doi: 10.1016/j.jacc.2006.08.046.

153. Zeng Q., Jiang S. Update in diagnosis and therapy of coexistent chronic obstructive pulmonary disease and chronic heart failure. J Thorac Dis. 2012 Jun 1;4(3):310-5. doi: 10.3978/j.issn.2072-1439.2012.01.09. 154.Rutten F.H., Cramer M.J., Grobbee D.E. Unrecognized heart failure in elderly patients with stable chronicobstructive pulmonary disease. Eur Heart J. 2005 Sep;26(18):1887-94. doi: 10.1093/eurheartj/ehi291.

155. McCullough P.A., Hollander J.E., Nowak R.M. et al. Uncovering heart failure in patients with a history of pulmonary disease: rationale for the early use of B-type natriuretic peptide in the emergency department. Acad Emerg Med. 2003 Mar;10(3):198-204. PMID: 12615582.

156. Chaouat A., Naeije R., Weitzenblum E. Pulmonary hypertension in COPD. Eur Respir J. 2008 Nov;32(5):1371-85. doi: 10.1183/09031936.00015608.

157. Pellicori P., Kallvikbacka-Bennett A., Zhang J. et al. Revisiting a classical clinical sign: jugular venous ultrasound. Int J Cardiol. 2014 Jan 1;170(3):364-70. doi: 10.1016/j.ijcard.2013.11.015.

158. Pellicori P., Goode K.M., Nicholls R. et al. Regional circulatory distribution of novel cardiac bio-markers and their relationships with haemodynamic measurements. Int J Cardiol. 2016 May 1;210:149-55. doi: 10.1016/j.ijcard.2016.02.081.

159. Villar Alvarez F., Mendez Bailon M., de Miguel Diez J. Chronic obstructive pulmonary disease and heart failure. Arch Bronconeumol. 2009 Aug;45(8):387-93. doi: 10.1016/j.arbres.2008.05.011.

160. Rutten F.H., Moons K.G., Cramer M.J. et al. Recognising heart failure in elderly patients with stablechronic obstructive pulmonary disease in primary care: cross sectional diagnostic study. BMJ. 2005 Dec 10;331(7529):1379. doi: 10.1136/bmj.38664.661181.55.

161. Arnaudis B., Lairez O., Escamilla R. et al. Impact of chronic obstructive pulmonary disease severity on symptoms and prognosis in patients with systolic heart failure. Clin Res Cardiol. 2012 Sep;101(9):717-26. doi: 10.1007/s00392-012-0450-4.

162. Mohamed Hoesein F.A., Zanen P., Lammers J.W. Lower limit of normal or FEV1/FVC

164. Steinacher R., Parissis J.T., Strohmer B. et al. Comparison between ATS/ERS age- and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res Cardiol. 2012 Aug;101(8):637-45. doi: 10.1007/s00392-012-0438-0.

165. Hansen J.E., Sun X.G., Wasserman K. Spirometric criteria for airway obstruction: Use percentage of FEV1/FVC ratio below the fifth percentile, not

166. Hardie J.A., Buist A.S., Vollmer W.M. et al. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002 Nov;20(5):1117-22. doi: 10.1183/09031936.02.00023202.

167. Celli B.R., Halbert R.J., Isonaka S. et al. Population impact of different definitions of airway obstruction.Eur Respir J. 2003 Aug;22(2):268-73. doi: 10.1183/09031936.03.00075102.

168. Onishi K., Yoshimoto D., Hagan G.W. et al. Prevalence of airflow limitation in outpatients with cardiovascular diseases in Japan. Int J Chron Obstruct Pulmon Dis. 2014 May 29;9:563-8. doi: 10.2147/ COPD.S59962

169. Wilson D., Adams R., Appleton S. et al. Difficulties identifying and targeting COPD and population- attributable risk of smoking for COPD: a population study. Chest. 2005 Oct;128(4):2035-42. doi: 10.1378/ chest.128.4.2035.

170. Karrasch S., Brüske I., Smith M.P., Thorand B., Huth C., Ladwig K.H., Kronenberg F., Heinrich J., Holle R., Peters A., Schulz H. What is the impact of different spirometric criteria on the prevalence of spirometrically defined COPD and its comorbidities? Results from the population-based KORA study. Int J Chron Obstruct Pulmon Dis. 2016 Aug 16;11:1881-94. doi: 10.2147/COPD.S104529.

171. Wollmer P., Frantz S., Engström G., Dencker M., Löfdahl C.G., Nihlén U. Fixed ratio or lower limit of normal for the FEV1 /VC ratio: relation to symptoms and extended lung function tests. Clin Physiol Funct Imaging. 2017 May;37(3):263-269. doi: 10.1111/cpf.12294.

172. Olofson J., Bake B., Tengelin M.N. et al. COPD ‘diagnosis’ based on spirometric reference equations. ClinRespir J. 2008 Oct;2(4):214-9. doi: 10.1111/j.1752-699X.2008.00065.x.

173. Marks G.B. Are reference equations for spirometry an appropriate criterion for diagnosing disease and predicting prognosis? Thorax. 2012 Jan;67(1):85-7. doi: 10.1136/thoraxjnl-2011-200584.

174. Wollmer P., Engström G. Fixed ratio or lower limit of normal as cut-off value for FEV1/VC: an outcome study. Respir Med. 2013 Sep;107(9):1460-2. doi: 10.1016/j.rmed.2013.06.016.

175. Güder G., Brenner S., Angermann C.E. et al. «GOLD or lower limit of normal definition? A comparison with expert-based diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study». Respir Res. 2012 Feb 6;13(1):13. doi: 10.1186/1465-9921-13-13.

176. Güder G., Brenner S., Störk S. et al. Chronic obstructive pulmonary disease in heart failure: accurate diagnosis and treatment. Eur J Heart Fail. 2014 Dec;16(12):1273-82. doi: 10.1002/ejhf.183.

177. Suskovic S., Kosnik M., Lainscak M. Heart failure and chronic obstructive pulmonary disease: Two for tea or tea for two? World J Cardiol. 2010 Oct 26;2(10):305-7. doi: 10.4330/wjc.v2.i10.305

178. Малявин А.Г., Адашева Т.В., Мартынов А.И. и др. Разработка интерактивной системы экспертной поддержки врачебных решений по рациональному назначению лекарственных препаратов при коморбидности. Ремедиум. 2016;11:38-41. doi: 10.21518/1561-5936-2016-11-52-55.

179. Адашева Т.В., Малявин А.Г., Мартынов А.И. Экспертная поддержка врачебных решений рациональ- ного назначения лекарственных препаратов в условиях полиморбидности. Терапия. 2016;6:24-26.

180. Norris V., Ambery C. Bronchodilation and safety of supratherapeutic doses of salbutamol or ipratropium bromide added to single dose GSK961081 in patients with moderate to severe COPD. Pulm Pharmacol Ther. 2013 Oct;26(5):574-80. doi: 10.1016/j.pupt.2013.03.009.

181. Wilchesky M., Ernst P., Brophy J.M. et al. Bronchodilator use and the risk of arrhythmia in COPD: part 2: reassessment in the larger Quebec cohort. Chest. 2012 Aug;142(2):305-311. doi: 10.1378/chest.11-1597. 182.Cazzola M., Imperatore F., Salzillo A. et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest. 1998 Aug;114(2):411-5.PMID: 9726723.

183.Xia N., Wang H., Nie X. Inhaled Long-Acting β2-Agonists Do Not Increase Fatal Cardiovascular Adverse Events in COPD: A Meta-Analysis. PLoS One. 2015 Sep 17;10(9):e0137904. doi: 10.1371/journal. pone.0137904.

184.Cazzola M., Calzetta L., Rinaldi B. et al. Management of Chronic Obstructive Pulmonary Disease in Patients with Cardiovascular Diseases. Drugs. 2017 May;77(7):721-732. doi: 10.1007/s40265-017-0731-3. 185.Minasian A.G., van den Elshout F.J., Dekhuijzen P.N. et al. Using the lower limit of normal instead of the conventional cutoff values to define predictors of pulmonary function impairment in subjects with chronicheart failure. Respir Care. 2016 Feb;61(2):173-83. doi: 10.4187/respcare.04101.

186. Minasian A.G., van den Elshout F.J., Dekhuijzen P.N. et al. Bronchodilator responsiveness in patientswith chronic heart failure. Heart Lung. 2013 May-Jun;42(3):208-14. doi: 10.1016/j.hrtlng.2012.11.007.

187. Rutten F.H., Cramer M.J., Lammers J.W. et al. Heart failure and chronic obstructive pulmonary disease: An ignored combination? Eur J Heart Fail. 2006 Nov;8(7):706-11. doi: 10.1016/j.e jheart.2006.01.010.

188. Gariani K., Delabays A., Perneger T.V. et al. Use of brain natriuretic peptide to detect previously unknown left ventricular dysfunction in patients with acute exacerbation of chronic obstructive pulmonary disease. Swiss Med Wkly. 2011 Nov 9;141:w13298. doi: 10.4414/smw.2011.13298.

189. Segreti A., Fiori E., Calzetta L. et al. The effect of indacaterol during an acute exacerbation of COPD. Pulm Pharmacol Ther. 2013 Dec;26(6):630-4. doi: 10.1016/j.pupt.2013.03.020.

190. Singh S., Loke Y.K., Furberg C.D. Inhaled anticholinergics and risk of major adverse cardiovascular events in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. JAMA. 2008 Sep 24;300(12):1439-50. doi: 10.1001/jama.300.12.1439.

191. Singh S., Loke Y.K., Enright P. et al. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic medications. Thorax. 2013 Jan;68(1):114-6. doi: 10.1136/thoraxjnl-2011-201275.

192. Halpin D.M., Dahl R., Hallmann C. et al. Tiotropium HandiHaler and Respimat in COPD: a pooled safety analysis. Int J Chron Obstruct Pulmon Dis. 2015 Feb 5;10:239-59. doi: 10.2147/COPD.S75146.

193. Cazzola M., Calzetta L., Rogliani P. et al. Tiotropium formulations and safety: a network meta-analysis.Ther Adv Drug Saf. 2017 Jan;8(1):17-30. doi: 10.1177/2042098616667304.

194. Calzetta L., Rogliani P., Matera M.G. et al. A Systematic Review With Meta-Analysis of Dual Bronchodilation With LAMA/LABA for the Treatment of Stable COPD. Chest. 2016 May;149(5):1181-96. doi: 10.1016/j.chest.2016.02.646.

195. Kerwin E., Ferguson G.T., Sanjar S. et al. Dual Bronchodilation with Indacaterol Maleate/Glycopyrronium Bromide Compared with Umeclidinium Bromide/Vilanterol in Patients with Moderate-to-Severe COPD: Results from Two Randomized, Controlled, Cross-over Studies. Lung. 2017 Dec;195(6):739-747. doi: 10.1007/s00408-017-0055-9.

196. Maggioni A.P., Orso F., Calabria S. et al. The real-world evidence of heart failure: findings from 41 413 patients of the ARNO database. Eur J Heart Fail. 2016 Apr;18(4):402-10. doi: 10.1002/ejhf.471.

197. Aizawa H., Imai S., Fushimi K. Factors associated with 30-day readmission of patients with heart failure from a Japanese administrative database. BMC Cardiovasc Disord. 2015 Oct 24;15:134. doi: 10.1186/ s12872-015-0127-9.

198. Dart R.A., Gollub S., Lazar J. et al. Treatment of systemic hypertension in patients with pulmonary disease: COPD and asthma. Chest. 2003 Jan;123(1):222-43. PMID: 12527626.

199. Cazzola M., Noschese P., D’Amato G. et al. The pharmacologic treatment of uncomplicated arterialhypertension in patients with airway dysfunction. Chest. 2002 Jan;121(1):230-41. PMID: 11796456. 200.Hill N.S. Fluid and electrolyte considerations in diuretic therapy for hypertensive patients with chronicobstructive pulmonary disease. Arch Intern Med. 1986 Jan;146(1):129-33. PMID: 2867747. ].

201. Chandy D., Aronow W.S., Banach M. Current perspectives on treatment of hypertensive patients with chronic obstructive pulmonary disease. Integr Blood Press Control. 2013 Jul 9;6:101-9. doi: 10.2147/ IBPC.S33982.

202. Bear R., Goldstein M., Phillipson E. et al. Effect of metabolic alkalosis on respiratory function in patients with chronic obstructive lung disease. Can Med Assoc J. 1977 Oct 22;117(8):900-3. PMID: 21028.

203. Lipworth B.J., McDevitt D.G., Struthers A.D. Prior treatment with diuretic augments the hypokalemic and electrocardiographic effects of inhaled albuterol. Am J Med. 1989 Jun;86(6 Pt 1):653-7. PMID: 2729315. 204.Wong C.S., Pavord I.D., Williams J. et al. Bronchodilator, cardiovascular, and hypokalaemic effects of fenoterol, salbutamol, and terbutaline in asthma. Lancet. 1990 Dec 8;336(8728):1396-9. PMID: 1978872.

205. Shrikrishna D., Astin R., Kemp P.R. et al. Renin-angiotensin system blockade: a novel therapeutic approach in chronic obstructive pulmonary disease. Clin Sci (Lond). 2012 Oct;123(8):487-98. doi: 10.1042/ CS20120081.

206. Israili .H., Hall W.D. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. A review of the literature and pathophysiology. Ann Intern Med. 1992 Aug 1;117(3):234- 42. doi: 10.7326/0003-4819-117-3-234

207. Sebastian J.L., McKinney W.P., Kaufman J. et al. Angiotensin-converting enzyme inhibitors and cough. Prevalence in an outpatient medical clinic population. Chest. 1991 Jan;99(1):36-9. doi: 10.1378/ chest.99.1.36.

208. Cazzola M., Noschese P., D’Amato G. et al. The pharmacologic treatment of uncomplicated arterial hypertension in patients with airway dysfunction. Chest. 2002 Jan;121(1):230-41. doi: 10.1378/ chest.121.1.230.

209. Mancini G.B., Etminan M., Zhang B. et al. Reduction of morbidity and mortality by statins, angiotensin- converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006 Jun 20;47(12):2554-60. doi: 10.1016/j.jacc.2006.04.039.

210. Petersen H., Sood A., Meek P.M. et al. Rapid lung function decline in smokers is a risk factor for COPD and is attenuated by angiotensin-converting enzyme inhibitor use. Chest. 2014 Apr;145(4):695-703. doi: 10.1378/chest.13-0799.

211. Mortensen E.M., Copeland L.A., Pugh M.J. et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009 Jun 3;10:45. doi: 10.1186/1465-9921-10-45.

212. Mancini G.B.J., Noschese P., D’Amato G. et al. Reduction of morbidity and mortality by statins, angiotensin- converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol. 2006 Jun 20;47(12):2554-60. doi: 10.1016/j.jacc.2006.04.039.

213. Kim J., Lee J.K., Heo E.Y. et al. The association of renin-angiotensin system blockades and pneumonia requiring admission in patients with COPD. Int J Chron Obstruct Pulmon Dis. 2016 Sep 9;11:2159-2166. doi: 10.2147/COPD.S104097.

214. Onder G., Penninx B.W., Balkrishgnan R. et al. Relation between use of angiotensin-converting enzyme inhibitors and muscle strength and physical function in older women: an observational study. Lancet. 2002 Mar 16;359(9310):926-30. PMID: 11918911.

215. Di Marco F., Guazzi M., Vicenzi M. et al. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm Pharmacol Ther. 2010 Jun;23(3):159-64. doi: 10.1016/j.pupt.2010.01.004.

216. Государственный реестр лекарственных средств https://grls.rosminzdrav.ru/

217. Sin D.D., Paul Man S.F. A curious case of b-blockers in chronic obstructive pulmonary disease. Arch Intern Med. 2010; 170: 849–850.

218. Stefan M.S., Bannuru R.R., Lessard D. et al. The impact of COPD on management and outcomes of patients hospitalized with acute myocardial infarction: a ten-year retrospective observational study. Chest 2012; 141:1441–1448.

219. Meyer A., Butler K., Long C. et al. Beta-blockers and COPD – inappropriate avoidance? Proceedings of Mid-South Regional Pharmacy Residents Conference. 2013; 66.

220. Stefan M.S., Rothenberg M.B., Priva A. et al. Association between beta-blocker therapy and outcomes in patients hospitalized with acute exacerbations of chronic obstructive lung disease with underlying ischemic heart disease, heart failure or hypertension. Thorax. 2012; 67: 977–984.

221. Baker J.G., Wilcox R.G. β-Blockers, heart disease and COPD: current controversies and uncertainties Thorax. 2017; 72: 271–276.

222. Angeloni E., Melina G., Roscitano A. et al. β-blockers improve survival of patients with chronic obstructive pulmonary disease after coronary artery bypass grafting. Ann Thorac Surg. 2013; 95: 525–531.

223. Gottlieb S.S., McCarter R.J., Vogel R.A. Effect of beta-blockade on mortality among high-risk and low- risk patients after myocardial infarction. N Engl J Med. 1998; 339: 489–497.

224. Mentz R.J., Wojdyla D., Fiuzat M. et al. Association of beta-blocker use and selectivity with outcomes in patients with heart failure and chronic obstructive pulmonary disease (from OPTIMIZE-HF). Am J Cardiol. 2013; 111: 582–587.

225. Mentz R.J., Schulte P.J., Fleg J.L. et al. Clinical characteristics, response to exercise training, and outcomes in patients with heart failure and chronic obstructive pulmonary disease: findings from heart failure and a controlled trial investigating outcomes of exercise training (HFACTION) Am Heart J. 2013;165: 193–199.

226. Rutten F.H., Zuithoff P.A., Hak E. et al. β-blockers may reduce mortality and risk of exacerbations inpatients with chronic obstructive pulmonary disease. Arch Intern Med. 2010; 170: 880–887.

227. van Gestel Y.R., Hoeks S.E., Sin D.D. et al. Impact of cardioselective bblockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am J Respir Crit Care Med. 2008; 178: 695–700.

228. Short P.M., Lipworth S.I., Elder D.H .et al. Effect of β blockers in treatment of chronic obstructive pulmonary disease: a retrospective cohort study. BMJ. 2011; 342: d2549.

229. Etminan M., Jafari S., Carleton B. Beta-blocker use and COPD mortality: a systematic review and meta- analysis. BMC Pulm Med. 2012; 12: 48.

230. Farland M.Z., Peters C.J., Williams J.D. et al. Beta-blocker use and incidence of chronic obstructive pulmonary disease exacerbations. Ann Pharmacother. 2013; 47: 651–656.

231. Callaerts-Vegh Z., Evans K.L., Dudekula N. et al. Effects of acute and chronic administration of beta- adrenoceptor ligands on airway function in a murine model of asthma. Proc Natl Acad Sci USA. 2004; 101: 4948–4953.

232. Nguyen L.P., Omoluabi O., Parra S. et al. Chronic exposure to betablockers attenuates inflammation and mucin content in a murine asthma model. Am J Respir Cell Mol Biol. 2008; 38: 256–262.

233. Bhatt S.P., Wells J.M., Kinney G.L. et al. β-Blockers are associated with a reduction in COPD exacerbations. Thorax. 2016; 71(1): 8-14.

234. Fuente-Maestu L., Calle M., Ortega-González A. Multicentric study on the beta-blocker use and relation with exacerbations in COPD. Respir Med. 2014; 108(5): 737-44.

235. Hawkins N.M., MacDonald M.R., Petrie M.C. et al. Bisoprolol in patients with heart failure and moderate to severe chronic obstructive pulmonary disease: a randomized controlled trial. Eur J Heart Fail. 2009; 11: 684–690.

236. Jabbour A., Macdonald P.S., Keogh A.M. et al. Differences between beta-blockers in patients with chronic heart failure and chronic obstructive pulmonary disease: a randomized crossover trial. J Am Coll Cardiol. 2010; 55: 1780–1787.

237. Dungen H.D., Apostolovi С.S., Inkrot S. et al. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011; 13: 670–680.

238. Sessa M., Mascolo A., Scavone C. et al. Long-Term Clinical Impact of Beta-Blockers Selectivity to carvedilol. Frontiers in Pharmacology. 2018; 9: 1212.

239. Hawkins N.M., Wang D., Petrie M.C. et al. Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail. 2010; 12(6): 557–65.

240. Dransfield M.T., McAllister D.A., Anderson J.A. et al. β-Blocker Therapy and Clinical Outcomes in Patients with Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. AnObservational Substudy of SUMMIT. Ann Am Thorac Soc. 2018; 15(5): 608-614.

241. Rinaldi B., Capuano A., Gritti G. et al. Effects of chronic administration of b-blockers on airway responsiveness in a murine model of heart failure. Pulm Pharmacol Ther. 2014; 28(2): 109–13.

242. Rinaldi B., Donniacuo M., Sodano L. et al. Effects of chronic treatment with the new ultra-long-acting β2-adrenoceptor agonist indacaterol alone or in combination with the β1 -adrenoceptor blocker metoprolol on cardiac remodelling. Br J Pharmacol. 2015; 172(14): 3627-37.

243. Khan M., Mohsin S., Avitabile D. et al. β-Adrenergic regulation of cardiac progenitor cell death versus survival and proliferation. Circ Res. 2013; 112(3): 476–86.

244. Rutten F.H., Hoes A.W. Chronic obstructive pulmonary disease: a slowly progressive cardiovascular disease masked by its pulmonary effects? Eur J Heart Fail. 2012; 14(4): 348–50.

245. Lin R., Peng H., Nguyen L.P. et al. Changes in b2-adrenoceptor and other signaling proteins produced by chronic administration of ‘β-blockers’ in a murine asthma model. Pulm Pharmacol Ther. 2008; 21(1): 115–24.

246. Salpeter S., Ormiston T., Salpeter E. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005; 19(4): CD003566.

247. Dezsi C.A., Szentes V. The Real Role of b-Blockers in Daily Cardiovascular Therapy. Am J Cardiovasc Drugs. 2007; 17: 361-373.

248. Lindenfeld J., Albert N.M., Boehmer J.P.et al. Heart Failure Society of America: 2010 Comprehensive Heart Failure Practice Guidelines. J Card Fail. 2010; 16: e1–e194.

249. Malerba M., Montuschi P., Radaeli A. et al. Role of beta-blockers in patients with COPD: current perspective. Drug Discov Today. 2015; 20: 129–35.